antibody

E-Cadherin RMab

MBS370063

0.1 mL (Concentrate)

215 USD

monoclonal

rabbit

nonconjugated

EP6

Antibody

E-Cadherin RMab

E-Cadherin

E-Cadherin RMab

Cadherin-1; Cadherin-1; cadherin-1; CAM 120/80; E-Cadherin; uvomorulin; cell-CAM 120/80; OTTHUMP00000174868; epithelial cadherin; cadherin 1, E-cadherin (epithelial); calcium-dependent adhesion protein, epithelial; cadherin 1, type 1, E-cadherin (epithelial); CAM 120/80; Epithelial cadherin; E-cadherin; Uvomorulin

CDH1; CDH1; UVO; CDHE; ECAD; LCAM; Arc-1; CD324; CDHE; UVO

CADH1_HUMAN

Monoclonal

IgG

EP6

Rabbit

Human

E-Cadherin is a rabbit monoclonal antibody derived from cell culture supernatant that is concentrated, dialyzed, filter sterilized and diluted in buffer pH 7.5, containing BSA and sodium azide as a preservative.

Store at 2 to 8 degree C in the dark.

Control: Pancreas, Lung Carcinoma. Localization: Membranous

Reactivity Note: Paraffin, Frozen

Cadherins are a class of transmembrane proteins. They play an important role in cell adhesion by ensuring cells within tissues are bound together. E-Cadherin is an adhesion protein that is expressed in cells of epithelial lineage. It stains positively in glandular epithelium as well as Adenocarcinomas of the lung and G.I. tract, and ovary. E-Cadherin has been useful in distinguishing Adenocarcinoma from Mesothelioma. It has also been shown to be positive in some Thyroid Carcinomas. It can be used to differentiate Ductal Carcinomas (positive for E-Cadherin) from Lobular Breast Carcinomas. Loss of E-Cadherin function or expression has been implicated in cancer progression and metastasis. E-Cadherin downregulation decreases the strength of cellular adhesion within a tissue, resulting in an increase in cellular motility. This may then allow cancer cells to cross the basement membrane and invade surrounding tissues. Loss of E-Cadherin expression has been suggested as a poor prognostic sign in Breast Carcinoma and Non-Small Cell Lung Carcinomas.

399166

P12830.3

P12830

P12830

97,456 Da

Adaptive Immunity Signaling Pathway (366160); Adherens Junction Pathway (83070); Adherens Junction Pathway (481); Adherens Junctions Interactions Pathway (119533); Apoptosis Pathway (105648); Apoptotic Cleavage Of Cell Adhesion Proteins Pathway (105680); Apoptotic Cleavage Of Cellular Proteins Pathway (105678); Apoptotic Execution Phase Pathway (105677); Arf6 Trafficking Events Pathway (137954); Bacterial Invasion Of Epithelial Cells Pathway (149807)

This gene is a classical cadherin from the cadherin superfamily. The encoded protein is a calcium dependent cell-cell adhesion glycoprotein comprised of five extracellular cadherin repeats, a transmembrane region and a highly conserved cytoplasmic tail. Mutations in this gene are correlated with gastric, breast, colorectal, thyroid and ovarian cancer. Loss of function is thought to contribute to progression in cancer by increasing proliferation, invasion, and/or metastasis. The ectodomain of this protein mediates bacterial adhesion to mammalian cells and the cytoplasmic domain is required for internalization. Identified transcript variants arise from mutation at consensus splice sites. [provided by RefSeq]

Function: Cadherins are calcium-dependent cell adhesion proteins. They preferentially interact with themselves in a homophilic manner in connecting cells; cadherins may thus contribute to the sorting of heterogeneous cell types. CDH1 is involved in mechanisms regulating cell-cell adhesions, mobility and proliferation of epithelial cells. Has a potent invasive suppressor role. It is a ligand for integrin alpha-E/beta-7. Ref.22E-Cad/CTF2 promotes non-amyloidogenic degradation of Abeta precursors. Has a strong inhibitory effect on APP C99 and C83 production. Ref.22. Subunit structure: Homodimer; disulfide-linked. Component of an E-cadherin/ catenin adhesion complex composed of at least E-cadherin/CDH1, beta-catenin/CTNNB1 or gamma-catenin/JUP, and potentially alpha-catenin/CTNNA1; the complex is located to adherens junctions. The stable association of CTNNA1 is controversial as CTNNA1 was shown not to bind to F-actin when assembled in the complex. Alternatively, the CTNNA1-containing complex may be linked to F-actin by other proteins such as LIMA1. Interaction with PSEN1, cleaves CDH1 resulting in the disassociation of cadherin-based adherens junctions (CAJs). Interacts with AJAP1, CTNND1 and DLGAP5. By similarity. Interacts with TBC1D2. Interacts with LIMA1. Interacts with CAV1. Interacts with the TRPV4 and CTNNB1 complex. By similarity. Ref.16 Ref.17 Ref.18 Ref.19 Ref.20 Ref.25 Ref.26. Subcellular location: Cell junction. Cell membrane; Single-pass type I membrane protein. Endosome. Golgi apparatus trans-Golgi network. Note: Colocalizes with DLGAP5 at sites of cell-cell contact in intestinal epithelial cells. Anchored to actin microfilaments through association with alpha-, beta- and gamma-catenin. Sequential proteolysis induced by apoptosis or calcium influx, results in translocation from sites of cell-cell contact to the cytoplasm. Colocalizes with RAB11A endosomes during its transport from the Golgi apparatus to the plasma membrane. Ref.4 Ref.18 Ref.21. Tissue specificity: Non-neural epithelial tissues. Induction: Expression is repressed by MACROD1. Ref.23. Post-translational modification: During apoptosis or with calcium influx, cleaved by a membrane-bound metalloproteinase (ADAM10), PS1/gamma-secretase and caspase-3 to produce fragments of about 38 kDa (E-CAD/CTF1), 33 kDa (E-CAD/CTF2) and 29 kDa (E-CAD/CTF3), respectively. Processing by the metalloproteinase, induced by calcium influx, causes disruption of cell-cell adhesion and the subsequent release of beta-catenin into the cytoplasm. The residual membrane-tethered cleavage product is rapidly degraded via an intracellular proteolytic pathway. Cleavage by caspase-3 releases the cytoplasmic tail resulting in disintegration of the actin microfilament system. The gamma-secretase-mediated cleavage promotes disassembly of adherens junctions. Ref.4 Ref.12 Ref.15N-glycosylation at Asn-637 is essential for expression, folding and trafficking. Involvement in disease: Defects in CDH1 are the cause of hereditary diffuse gastric cancer (HDGC) [. MIM:137215]. An autosomal dominant cancer predisposition syndrome with increased susceptibility to diffuse gastric cancer. Diffuse gastric cancer is a malignant disease characterized by poorly differentiated infiltrating lesions resulting in thickening of the stomach. Malignant tumors start in the stomach, can spread to the esophagus or the small intestine, and can extend through the stomach wall to nearby lymph nodes and organs. It also can metastasize to other parts of the body. Note=Heterozygous germline mutations CDH1 are responsible for familial cases of diffuse gastric cancer. Somatic mutations in the has also been found in patients with sporadic diffuse gastric cancer and lobular breast cancer. Ref.36 Ref.41Defects in CDH1 are a cause of susceptibility to endometrial cancer (ENDMC) [. MIM:608089].Defects in CDH1 are a cause of susceptibility to ovarian cancer (OC) [. MIM:167000]. Ovarian cancer common malignancy originating from ovarian tissue. Although many histologic types of ovarian neoplasms have been described, epithelial ovarian carcinoma is the most common form. Ovarian cancers are often asymptomatic and the recognized signs and symptoms, even of late-stage disease, are vague. Consequently, most patients are diagnosed with advanced disease. Sequence similarities: Contains 5 cadherin domains. Sequence caution: The sequence AAA61259.1 differs from that shown. Reason: Frameshift at positions 16, 22, 25, 28, 31, 34, 52, 67, 73, 76, 94, 102, 633 and 636.

0.1 mL (Concentrate)

215 USD

5 + Control Slides

230

3 mL

235

7 mL

375

0.5 mL (Concentrate)

510